Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue from product sales	$ 73	$ 55	$ 85	$ 168
Collaboration revenue	14	82	18	163
Total revenue	87	137	103	331
Cost of product sales	392	77	409	221
Cost of collaboration revenue	0	85	1	88
Total cost of revenue	392	162	410	309
Gross (loss) profit	(305)	(25)	(307)	22
Research and development expense	2,352	2,567	4,954	4,814
Selling, general and administrative expense	2,540	3,640	5,280	6,564
Intangible asset impairment expense	3,905	0	3,905	0
Restructuring costs	292	0	292	0
Operating loss	(10,319)	(7,359)	(16,987)	(14,223)
Other income (expense):
Warrant revaluation income (expense)	2,254	602	7,511	(1,061)
Other expense	(31)	0	(31)	0
Interest income	4	1	8	3
Loss before income taxes	(8,092)	(6,756)	(9,499)	(15,281)
Income tax benefit	0	0	0	0
Net loss	$ (8,092)	$ (6,756)	$ (9,499)	$ (15,281)
Per Share Information:
Basic net loss (usd per share)	$ (0.18)	$ (0.17)	$ (0.22)	$ (0.37)
Diluted net loss (usd per share)	$ (0.18)	$ (0.17)	$ (0.26)	$ (0.37)
Weighted average number of common shares outstanding:
Basic weighted average number of common shares outstanding, shares	43,898,785	40,889,732	43,898,785	40,875,704
Diluted weighted average number of common shares outstanding, shares	43,898,785	40,889,732	43,934,819	40,875,704
Affiliated Entity
Research and development expense	$ 925	$ 1,127	$ 2,249	$ 2,867